<ul>
<li>通用电气航空：卡塔尔交易推动数十亿美元增长引擎</li>
</ul>
<p>通用电气医疗科技（NASDAQ: GEHC）高管表示，尽管第一季度表现令人失望，导致全年指引下调，但公司对长期增长前景依然充满信心，主要面临的短期挑战是通货膨胀带来的成本压力。</p>
<p>在拉斯维加斯举行的美国银行证券医疗会议上，通用电气医疗的副总裁兼首席财务官詹姆斯·萨卡罗表示，公司 “最终不得不下调年度指引”，他表示管理层对此 “非常重视”。他将下调归因于公司需要在展望中反映的 “非常剧烈的通货膨胀成本”。</p>
<ul>
<li>霍尼韦尔的拆分：HON 股票对投资者来说是个甜蜜的交易吗？</li>
</ul>
<p>尽管如此，萨卡罗强调了几个强劲的领域。他表示，第一季度订单同比增长略超过 1%，而去年同期的比较为 10%，销售额也达到了公司预期范围的高端。他还表示，公司产品管道基本按计划推进，通用电气医疗在其心跳管理系统方面取得了进展。</p>
<h2>通货膨胀和定价仍然是投资者关注的关键</h2>
<p>萨卡罗表示，通用电气医疗的产品组合特别容易受到某些成本压力的影响，因为其产品高度工程化，并且包括全球采购的组件。他提到货运、物流、燃料、氦气、稀土元素和内存芯片等领域的压力。</p>
<ul>
<li>超声波减肥：通用电气医疗与诺和诺德的合作</li>
</ul>
<p>根据萨卡罗的说法，公司在货运和物流成本方面遭受了约 1 亿美元的影响，以及与中东冲突相关的约 5000 万美元的其他成本。他还指出内存芯片的通货膨胀，表示公司在该成本类别上看到了一亿美元的增加。</p>
<p>萨卡罗表示，通用电气医疗假设当前的内存芯片价格将持续到今年剩余时间，并在其预测中建立了额外的缓冲和应急措施。他表示，公司已经锁定了供应，并且迄今为止没有看到内存供应的限制。</p>
<p>在定价方面，萨卡罗表示公司在重新定价积压订单方面能力有限，但在新订单方面灵活性更大。他说：“我们目前的成本与之前相比发生了结构性变化”，并补充说通用电气医疗在新业务决策中反映了这些更高的成本。</p>
<h2>资本配置包括回购、研发和并购</h2>
<p>萨卡罗表示，通用电气医疗在第一季度以约 70 美元的价格回购了股票，采用基于折现现金流的内在价值模型。他表示，公司将回购视为其持续资本部署战略的一部分，在对业务进行再投资和追求有针对性的收购之后。</p>
<p>他还提到在第一季度完成了 Intelerad 的收购，称其在战略和财务上都是增值的。萨卡罗表示，公司还继续支付股息。</p>
<h2>业务结构和患者护理解决方案审查</h2>
<p>高级成像解决方案的总裁兼首席执行官菲利普·D·拉克利夫讨论了公司将业务合并为高级成像解决方案的决定。他表示，客户正在向更横向的护理连续体转变，从初步扫描和病变检测到诊断、规划和治疗。拉克利夫表示，通用电气医疗看到利用数据和人工智能改善工作流程效率和患者结果的机会。</p>
<p>萨卡罗还提到了患者护理解决方案（PCS），表示该部门在第一季度表现令人失望，尽管基本符合预期。他表示，8% 的下降和业务报告的利润水平 “不是可接受的表现阈值”。公司专注于改善业务，同时评估 “战略选择” 和 PCS 在通用电气医疗中的角色。</p>
<p>萨卡罗表示，PCS 与公司其他业务的关联性低于超声波和成像，并将其描述为相对于新合并的成像业务和药物诊断而言的低利润业务。</p>
<h2>产品管道和成像前景</h2>
<p>拉克利夫表示，自公司分拆以来，通用电气医疗超过 30 亿美元的投资开始显现成效。他表示，公司正进入一个在 CT、MR、超声波和影像引导治疗方面显著产品创新的时期，预计在未来六到 18 个月内推出重要的新产品。</p>
<p>他将光子计数 CT 描述为一个 “蓝海” 机会，而不仅仅是通用电气医疗现有基础的替代周期。拉克利夫表示，公司在光子计数 CT 方面的潜在管道 “远超 1 亿美元”，并预计在 2026 年下半年及 2027 年实现收入转化。</p>
<p>萨卡罗表示，预计新产品将支持利润改善，因为它们通常比前代产品价格更高、成本更低。他还提到通过心跳管理系统的精益运营改进和一般成本控制将有助于长期利润机会。</p>
<h2>中国和 Flircado 的进展</h2>
<p>萨卡罗表示，通用电气医疗在中国进行了变革，包括引入 Will Song 作为领导者，专注于商业执行、政府事务和市场细分。他表示，公司正在提高胜率，并看到更具建设性的经济背景，尽管并未改变对中国市场下滑的预期。</p>
<p>拉克利夫表示，中国的情绪已经稳定，并指出通用电气医疗在该国的大规模布局，包括数千名员工和多个制造工厂。</p>
<p>萨卡罗还表示，Flircado 取得了进展，其年运行率从约 2500 万美元上升到一个季度后大约 4600 万美元。他重申公司在 2028 年前实现超过 5 亿美元收入的目标，同时强调采用将谨慎管理，以确保客户获得积极体验。</p>
<p>他说公司正在处理报销、放射药学制造工作流程和客户现场采用等关键因素，以推动产品上市。</p>
<p>展望未来，萨卡罗表示，GE HealthCare 预计在今年剩余时间内订单增长将更高，并继续瞄准中个位数的中期销售增长。他表示，公司仍专注于创新和运营执行，同时应对波动的成本环境。</p>
<h2>关于 GE HealthCare Technologies NASDAQ: GEHC</h2>
<p>GE HealthCare Technologies NASDAQ: GEHC 是一家全球医疗技术和诊断公司，开发、制造和销售广泛的产品和服务，服务于医疗保健提供者。其产品组合以诊断成像系统为中心，包括 MRI、CT、PET 和 X 射线设备，以及超声设备。该公司还提供患者监护和麻醉输送系统、介入和外科成像解决方案，以及用于临床护理和研究环境的分子成像技术。</p>
<p>除了硬件，GE HealthCare 还提供软件、分析和生命周期服务，旨在改善临床工作流程和设备正常运行时间。</p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GE HealthCare Technologies 吗？</h2>
<p>在考虑 GE HealthCare Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 GE HealthCare Technologies 并不在名单上。</p>
<p>虽然 GE HealthCare Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GEHC

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>GE HealthCare Technologies 尽管在第一季度遭遇挫折并因通胀压力下调了全年指引，但仍对长期增长持乐观态度。首席财务官 James Saccaro 强调订单增长了 1% 和强劲的销售，同时提到物流和内存芯片带来的显著成本影响。公司专注于资本配置，包括股票回购和研发，并预计在未来几个月将有显著的产品创新</p>

<ul>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>通用电气航空：卡塔尔交易推动数十亿美元增长引擎</li>
</ul>
</div><p>GE HealthCare Technologies NASDAQ: GEHC executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge.</p>
<div class="lb-trans"><p>通用电气医疗科技（NASDAQ: GEHC）高管表示，尽管第一季度表现令人失望，导致全年指引下调，但公司对长期增长前景依然充满信心，主要面临的短期挑战是通货膨胀带来的成本压力。</p>
</div><p>Speaking at a Bank of America Securities healthcare conference in Las Vegas, James Saccaro, GE HealthCare’s vice president and chief financial officer, said the company “ended up having to lower guidance for the year,” a move he said management takes “very seriously.” He attributed the reduction to “very dramatic inflationary costs” that the company needed to reflect in its outlook.</p>
<div class="lb-trans"><p>在拉斯维加斯举行的美国银行证券医疗会议上，通用电气医疗的副总裁兼首席财务官詹姆斯·萨卡罗表示，公司 “最终不得不下调年度指引”，他表示管理层对此 “非常重视”。他将下调归因于公司需要在展望中反映的 “非常剧烈的通货膨胀成本”。</p>
</div><ul>
<li>Honeywell’s Breakup: Is HON Stock a Sweet Deal for Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>霍尼韦尔的拆分：HON 股票对投资者来说是个甜蜜的交易吗？</li>
</ul>
</div><p>Even so, Saccaro highlighted several areas of strength. He said first-quarter orders grew a little over 1% against a 10% comparison from the prior year, while sales came in at the high end of the company’s expected range. He also said the company’s product pipeline is largely on track and that GE HealthCare has made progress with its Heartbeat management system.</p>
<div class="lb-trans"><p>尽管如此，萨卡罗强调了几个强劲的领域。他表示，第一季度订单同比增长略超过 1%，而去年同期的比较为 10%，销售额也达到了公司预期范围的高端。他还表示，公司产品管道基本按计划推进，通用电气医疗在其心跳管理系统方面取得了进展。</p>
</div><h2>Inflation and Pricing Remain Key Investor Focus</h2>
<div class="lb-trans"><h2>通货膨胀和定价仍然是投资者关注的关键</h2>
</div><p>Saccaro said GE HealthCare’s portfolio is particularly exposed to certain cost pressures because its products are highly engineered and include components sourced globally. He cited freight, logistics, fuel, helium, rare earth elements and memory chips as areas of pressure.</p>
<div class="lb-trans"><p>萨卡罗表示，通用电气医疗的产品组合特别容易受到某些成本压力的影响，因为其产品高度工程化，并且包括全球采购的组件。他提到货运、物流、燃料、氦气、稀土元素和内存芯片等领域的压力。</p>
</div><ul>
<li>Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play</li>
</ul>
<div class="lb-trans"><ul>
<li>超声波减肥：通用电气医疗与诺和诺德的合作</li>
</ul>
</div><p>According to Saccaro, the company saw about $100 million of impact from freight and logistics costs, along with about $50 million in other costs tied to the Middle East conflict. He also pointed to memory chip inflation, saying the company had seen a $100 million increase in that cost category.</p>
<div class="lb-trans"><p>根据萨卡罗的说法，公司在货运和物流成本方面遭受了约 1 亿美元的影响，以及与中东冲突相关的约 5000 万美元的其他成本。他还指出内存芯片的通货膨胀，表示公司在该成本类别上看到了一亿美元的增加。</p>
</div><p>Saccaro said GE HealthCare has assumed current memory chip prices continue through the rest of the year, with additional buffers and contingencies built into its forecast. He said the company has supply locked in and has not seen memory supply constraints to date.</p>
<div class="lb-trans"><p>萨卡罗表示，通用电气医疗假设当前的内存芯片价格将持续到今年剩余时间，并在其预测中建立了额外的缓冲和应急措施。他表示，公司已经锁定了供应，并且迄今为止没有看到内存供应的限制。</p>
</div><p>On pricing, Saccaro said the company has limited ability to reprice backlog, but greater flexibility on new orders. “Our costs at this moment in time have structurally changed versus prior,” he said, adding that GE HealthCare is reflecting those higher costs in decisions on new business.</p>
<div class="lb-trans"><p>在定价方面，萨卡罗表示公司在重新定价积压订单方面能力有限，但在新订单方面灵活性更大。他说：“我们目前的成本与之前相比发生了结构性变化”，并补充说通用电气医疗在新业务决策中反映了这些更高的成本。</p>
</div><h2>Capital Allocation Includes Buybacks, R&amp;D and M&amp;A</h2>
<div class="lb-trans"><h2>资本配置包括回购、研发和并购</h2>
</div><p>Saccaro said GE HealthCare repurchased shares in the first quarter at around $70, using an intrinsic value model based on discounted cash flow. He said the company views buybacks as part of its ongoing capital deployment strategy, after reinvesting in the business and pursuing targeted acquisitions.</p>
<div class="lb-trans"><p>萨卡罗表示，通用电气医疗在第一季度以约 70 美元的价格回购了股票，采用基于折现现金流的内在价值模型。他表示，公司将回购视为其持续资本部署战略的一部分，在对业务进行再投资和追求有针对性的收购之后。</p>
</div><p>He also pointed to the closing of Intelerad in the first quarter, describing it as strategically and financially accretive. Saccaro said the company also continues to pay a dividend.</p>
<div class="lb-trans"><p>他还提到在第一季度完成了 Intelerad 的收购，称其在战略和财务上都是增值的。萨卡罗表示，公司还继续支付股息。</p>
</div><h2>Business Structure and PCS Review</h2>
<div class="lb-trans"><h2>业务结构和患者护理解决方案审查</h2>
</div><p>Philip D. Rackliffe, president and CEO of Advanced Imaging Solutions, discussed the company’s decision to combine businesses into Advanced Imaging Solutions. He said customers are moving toward a more horizontal care continuum, from initial scans and lesion detection through diagnosis, planning and therapy. Rackliffe said GE HealthCare sees an opportunity to use data and AI to improve workflow efficiency and patient outcomes.</p>
<div class="lb-trans"><p>高级成像解决方案的总裁兼首席执行官菲利普·D·拉克利夫讨论了公司将业务合并为高级成像解决方案的决定。他表示，客户正在向更横向的护理连续体转变，从初步扫描和病变检测到诊断、规划和治疗。拉克利夫表示，通用电气医疗看到利用数据和人工智能改善工作流程效率和患者结果的机会。</p>
</div><p>Saccaro also addressed Patient Care Solutions, or PCS, saying the segment had a disappointing first quarter, though largely in line with expectations. He said an 8% decline and the margin level reported by the business were “not an acceptable threshold of performance.” The company is focused on improving the business, while also evaluating “strategic alternatives” and the role PCS plays within GE HealthCare.</p>
<div class="lb-trans"><p>萨卡罗还提到了患者护理解决方案（PCS），表示该部门在第一季度表现令人失望，尽管基本符合预期。他表示，8% 的下降和业务报告的利润水平 “不是可接受的表现阈值”。公司专注于改善业务，同时评估 “战略选择” 和 PCS 在通用电气医疗中的角色。</p>
</div><p>Saccaro said PCS is less linked to the company’s other businesses than ultrasound and imaging, and described it as a lower-margin business relative to the newly combined imaging business and Pharmaceutical Diagnostics.</p>
<div class="lb-trans"><p>萨卡罗表示，PCS 与公司其他业务的关联性低于超声波和成像，并将其描述为相对于新合并的成像业务和药物诊断而言的低利润业务。</p>
</div><h2>Product Pipeline and Imaging Outlook</h2>
<div class="lb-trans"><h2>产品管道和成像前景</h2>
</div><p>Rackliffe said GE HealthCare’s more than $3 billion of investment since its spin-off is beginning to show results. He said the company is entering a period of significant product innovation across CT, MR, ultrasound and image-guided therapies, with material new products expected over the next six to 18 months.</p>
<div class="lb-trans"><p>拉克利夫表示，自公司分拆以来，通用电气医疗超过 30 亿美元的投资开始显现成效。他表示，公司正进入一个在 CT、MR、超声波和影像引导治疗方面显著产品创新的时期，预计在未来六到 18 个月内推出重要的新产品。</p>
</div><p>He described photon counting CT as a “blue ocean” opportunity rather than primarily a replacement cycle for GE HealthCare’s installed base. Rackliffe said the company had a potential funnel “well in excess of $100 million” for photon counting CT and expects revenue conversion in the back half of 2026 and into 2027.</p>
<div class="lb-trans"><p>他将光子计数 CT 描述为一个 “蓝海” 机会，而不仅仅是通用电气医疗现有基础的替代周期。拉克利夫表示，公司在光子计数 CT 方面的潜在管道 “远超 1 亿美元”，并预计在 2026 年下半年及 2027 年实现收入转化。</p>
</div><p>Saccaro said new products are expected to support margin improvement because they generally carry higher prices and lower costs than predecessor products. He also cited lean operating improvements through Heartbeat and general cost discipline as contributors to longer-term margin opportunity.</p>
<div class="lb-trans"><p>萨卡罗表示，预计新产品将支持利润改善，因为它们通常比前代产品价格更高、成本更低。他还提到通过心跳管理系统的精益运营改进和一般成本控制将有助于长期利润机会。</p>
</div><h2>China and Flircado Progress</h2>
<div class="lb-trans"><h2>中国和 Flircado 的进展</h2>
</div><p>Saccaro said GE HealthCare has made changes in China, including bringing in Will Song as leader, with a focus on commercial execution, government affairs and targeting market segments. He said the company is improving win rates and seeing a more constructive economic backdrop, though it has not changed its expectation that China will be down.</p>
<div class="lb-trans"><p>萨卡罗表示，通用电气医疗在中国进行了变革，包括引入 Will Song 作为领导者，专注于商业执行、政府事务和市场细分。他表示，公司正在提高胜率，并看到更具建设性的经济背景，尽管并未改变对中国市场下滑的预期。</p>
</div><p>Rackliffe said sentiment in China has stabilized and noted GE HealthCare’s large footprint in the country, including thousands of employees and multiple manufacturing plants.</p>
<div class="lb-trans"><p>拉克利夫表示，中国的情绪已经稳定，并指出通用电气医疗在该国的大规模布局，包括数千名员工和多个制造工厂。</p>
</div><p>Saccaro also said Flircado has made progress, with its annual run rate rising from about $25 million to roughly $46 million one quarter later. He reiterated the company’s focus on reaching more than $500 million in revenue by 2028, while emphasizing that adoption will be managed carefully to ensure customers have a positive experience.</p>
<div class="lb-trans"><p>萨卡罗还表示，Flircado 取得了进展，其年运行率从约 2500 万美元上升到一个季度后大约 4600 万美元。他重申公司在 2028 年前实现超过 5 亿美元收入的目标，同时强调采用将谨慎管理，以确保客户获得积极体验。</p>
</div><p>He said the company is working through reimbursement, radiopharmacy manufacturing workflow and customer-site adoption as key factors in the launch.</p>
<div class="lb-trans"><p>他说公司正在处理报销、放射药学制造工作流程和客户现场采用等关键因素，以推动产品上市。</p>
</div><p>Looking ahead, Saccaro said GE HealthCare expects higher order growth through the rest of the year and continues to target mid-single-digit sales growth over the medium term. He said the company remains focused on innovation and operating execution while navigating a volatile cost environment.</p>
<div class="lb-trans"><p>展望未来，萨卡罗表示，GE HealthCare 预计在今年剩余时间内订单增长将更高，并继续瞄准中个位数的中期销售增长。他表示，公司仍专注于创新和运营执行，同时应对波动的成本环境。</p>
</div><h2>About GE HealthCare Technologies NASDAQ: GEHC</h2>
<div class="lb-trans"><h2>关于 GE HealthCare Technologies NASDAQ: GEHC</h2>
</div><p>GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.</p>
<div class="lb-trans"><p>GE HealthCare Technologies NASDAQ: GEHC 是一家全球医疗技术和诊断公司，开发、制造和销售广泛的产品和服务，服务于医疗保健提供者。其产品组合以诊断成像系统为中心，包括 MRI、CT、PET 和 X 射线设备，以及超声设备。该公司还提供患者监护和麻醉输送系统、介入和外科成像解决方案，以及用于临床护理和研究环境的分子成像技术。</p>
</div><p>In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.</p>
<div class="lb-trans"><p>除了硬件，GE HealthCare 还提供软件、分析和生命周期服务，旨在改善临床工作流程和设备正常运行时间。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GE HealthCare Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GE HealthCare Technologies 吗？</h2>
</div><p>Before you consider GE HealthCare Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GE HealthCare Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GE HealthCare Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 GE HealthCare Technologies 并不在名单上。</p>
</div><p>While GE HealthCare Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GE HealthCare Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GE HealthCare Technologies Sticks to Growth Story After Inflation-Driven Guidance Cut

Market Beat

GE HealthCare Tech

GE航空航天

美国银行

霍尼韦尔

诺和诺德公司

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Honeywell International - WI

GE HealthCare Technologies 在因通胀导致指导下调后仍坚持其增长故事